U.S. Markets closed
  • S&P 500

    3,585.62
    -54.85 (-1.51%)
     
  • Dow 30

    28,725.51
    -500.09 (-1.71%)
     
  • Nasdaq

    10,575.62
    -161.88 (-1.51%)
     
  • Russell 2000

    1,664.72
    -10.21 (-0.61%)
     
  • Crude Oil

    79.74
    +0.25 (+0.31%)
     
  • Gold

    1,668.30
    -3.70 (-0.22%)
     
  • Silver

    19.01
    -0.02 (-0.13%)
     
  • EUR/USD

    0.9803
    -0.0016 (-0.1667%)
     
  • 10-Yr Bond

    3.8040
    +0.0570 (+1.52%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1174
    +0.0050 (+0.4525%)
     
  • USD/JPY

    144.7030
    +0.2600 (+0.1800%)
     
  • BTC-USD

    19,238.78
    -21.62 (-0.11%)
     
  • CMC Crypto 200

    443.49
    +0.06 (+0.01%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    25,937.21
    -484.89 (-1.84%)
     

Immunic Says Potential Inflammatory Disease Candidate Is Safe, Tolerable In Healthy Participants

·1 min read
  • Immunic Inc (NASDAQ: IMUXannounced unblinded safety, tolerability, and pharmacokinetic (PK) results from Part A (single ascending doses, SAD) and Part B (multiple ascending doses, MAD) of its phase 1 trial of IMU-856 in healthy human subjects.

  • In the SAD part of phase 1 clinical trial, healthy human subjects were randomized to either placebo or active treatment with single ascending doses of IMU-856 at 10 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg.

  • Single ascending doses of IMU-856 were found to be safe and well-tolerated, and no maximum tolerated dose was reached.

  • Related: Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger.

  • No serious adverse events occurred.

  • Multiple ascending doses of IMU-856 were found to be safe and well-tolerated, and no maximum tolerated dose was reached. Treatment-emergent adverse events were primarily mild in severity.

  • The ongoing Part C of the phase 1 program is designed to assess the safety and tolerability of IMU-856 in patients with celiac disease during periods of gluten-free diet and gluten challenge.

  • Approximately 42 patients are planned to be enrolled in two consecutive cohorts with 80 mg or 160 mg of IMU-856 given once daily over 28 days.

  • Price Action: IMUX shares are down 8.05% at $3.54 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.